脂蛋白分离:首个FDA批准的治疗脂蛋白升高的方法(a)

Journal of Clinical Cardiology Pub Date : 2020-10-15 DOI:10.33696/cardiology.1.002

Anne K. Nugent, Jessica V. Gray, L. Gorby, P. Moriarty

{"title":"脂蛋白分离:首个FDA批准的治疗脂蛋白升高的方法(a)","authors":"Anne K. Nugent, Jessica V. Gray, L. Gorby, P. Moriarty","doi":"10.33696/cardiology.1.002","DOIUrl":null,"url":null,"abstract":"Lipoprotein(a) [Lp(a)] is a genetically determined lowdensity lipoprotein (LDL) particle that is comprised of apolipoprotein(a) [apo(a)] and apolipoprotein B-100 (apoB) moieties. It is well-established that elevated Lp(a) is an independent risk factor for cardiovascular disease (CVD). It is associated with an increased risk of myocardial infarction, aortic valve stenosis, ischemic stroke and peripheral vascular disease [1,2].","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)\",\"authors\":\"Anne K. Nugent, Jessica V. Gray, L. Gorby, P. Moriarty\",\"doi\":\"10.33696/cardiology.1.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lipoprotein(a) [Lp(a)] is a genetically determined lowdensity lipoprotein (LDL) particle that is comprised of apolipoprotein(a) [apo(a)] and apolipoprotein B-100 (apoB) moieties. It is well-established that elevated Lp(a) is an independent risk factor for cardiovascular disease (CVD). It is associated with an increased risk of myocardial infarction, aortic valve stenosis, ischemic stroke and peripheral vascular disease [1,2].\",\"PeriodicalId\":15510,\"journal\":{\"name\":\"Journal of Clinical Cardiology\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.33696/cardiology.1.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33696/cardiology.1.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

摘要

脂蛋白(a) [Lp(a)]是一种由遗传决定的低密度脂蛋白(LDL)颗粒，由载脂蛋白(a) [apo(a)]和载脂蛋白B-100 (apoB)组成。血压升高是心血管疾病(CVD)的独立危险因素。它与心肌梗死、主动脉瓣狭窄、缺血性卒中和周围血管疾病的风险增加有关[1,2]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a)

Lipoprotein(a) [Lp(a)] is a genetically determined lowdensity lipoprotein (LDL) particle that is comprised of apolipoprotein(a) [apo(a)] and apolipoprotein B-100 (apoB) moieties. It is well-established that elevated Lp(a) is an independent risk factor for cardiovascular disease (CVD). It is associated with an increased risk of myocardial infarction, aortic valve stenosis, ischemic stroke and peripheral vascular disease [1,2].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Cardiology

自引率

0.00%

发文量